Arcutis Biotherapeutics (ARQT) EBT Margin (2022 - 2026)
Arcutis Biotherapeutics (ARQT) posted quarterly EBT Margin of 10.63% for Q1 2026, up 2819.0% year-over-year from 0.36% in Q1 2025, and down 177.04% quarter-over-quarter from 13.8% in Q4 2025.
Arcutis Biotherapeutics (ARQT) EBT Margin (2022 - 2026) Analysis & Trends
Arcutis Biotherapeutics' EBT Margin history runs 5 years deep, the most recent figure standing at 10.63% for Q1 2026.
- In Q1 2026, EBT Margin rose 2819.0% year-over-year to 10.63%; the TTM figure through Mar 2026 stood at 0.33% (up 6150.0% YoY), while the FY2025 annual figure was 3.98%, up 7972.0% from the prior year.
- EBT Margin for Q1 2026 stood at 10.63%, down from 13.8% in the prior quarter.
- The five-year high for EBT Margin was 13.8% in Q4 2025, with the low at 14856.41% in Q3 2022.
- The 5-year median for EBT Margin is 109.53% (2023), against an average of 1493.65%.
- The sharpest annual moves came in 2023 and 2024: EBT Margin soared 1474688 bps in 2023, then jumped 1672 bps in 2024.
- Arcutis Biotherapeutics' EBT Margin stood at 2432.25% in 2022, then surged by 94 bps to 150.77% in 2023, then jumped by 90 bps to 15.09% in 2024, then soared by 191 bps to 13.8% in 2025, then slumped by 177 bps to 10.63% in 2026.
- Business Quant data shows ARQT's EBT Margin at 10.63% in Q1 2026, 13.8% in Q4 2025, and 7.55% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | Arcutis Biotherapeutics | 3.29 Bn | 3.05 Bn | 118.92 Mn | 11.66% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.66% |
| Mar 31, 2026 | -10.63% |
| Dec 31, 2025 | 13.80% |
| Sep 30, 2025 | 7.55% |
| Jun 30, 2025 | -19.07% |
| Mar 31, 2025 | -38.81% |
| Dec 31, 2024 | -15.09% |
| Sep 30, 2024 | -92.81% |
| Jun 30, 2024 | -169.59% |
| Mar 31, 2024 | -162.54% |
| Dec 31, 2023 | -150.77% |
| Sep 30, 2023 | -109.53% |
| Jun 30, 2023 | -1,488.28% |
| Mar 31, 2023 | -2,880.26% |
| Dec 31, 2022 | -2,432.25% |
| Sep 30, 2022 | -14,856.41% |